{"url_path":"/sec/odtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274290-index.html","accession_number":"0001193125-26-274290","cik":"0001882782","ticker":"ODTX","issuer_name":"Odyssey Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274290-index.html","primary_entity_key":"0001882782","primary_entity_name":"Odyssey Therapeutics, Inc."},"word_count":360,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n[3.1](https://www.sec.gov/Archives/edgar/data/1882782/000119312526216899/odtx-ex3_1.htm)\n\n \n\nNinth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-43270), filed on May 11, 2026).\n\n[3.2](https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-ex3_4.htm)\n\n \n\nAmended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-295141), filed on April 17, 2026).\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-ex4_1.htm)\n\n \n\nForm of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-295141), filed on April 17, 2026).\n\n[4.2](https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-ex4_2.htm)\n\n \n\nWarrant to Purchase Stock, issued to Banc of California (formerly Pacific Western Bank) (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-295141), filed on April 17, 2026).\n\n[31.1](odtx-ex31_1.htm)*\n\n \n\nCertification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n[31.2](odtx-ex31_2.htm)*\n\n \n\nCertification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n[32.1](odtx-ex32_1.htm)*\n\n \n\nCertification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n[32.2](odtx-ex32_2.htm)*\n\n \n\nCertification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n100\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nOdyssey Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: June 17, 2026\n\n \n\nBy:\n\n/s/ Gary D. Glick\n\n \n\n \n\n \n\nGary D. Glick, Ph.D.\n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: June 17, 2026\n\n \n\nBy:\n\n/s/ Jason Haas\n\n \n\n \n\n \n\nJason Haas\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n101"}